NEW YORK (GenomeWeb) – Germany's InfanDx announced it has received the go-ahead from an ethics committee to proceed with a verification study for its metabolomics-based test for brain damage from perinatal asphyxia, or oxygen deficit during birth.

The study, called the Asphyxia-Associated Metabolite Biomarker Investigation (AAMBI) aims to confirm in humans the presence of metabolite profiles found in animal studies that indicated brain damage from asphyxia.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Seattle Times writes that pharmacogenomics testing can help choose medications that may work best for people with depression.

Researchers report that deleting one gene from butterflies affects their wing coloration patterns, according to the Washington Post.

In PNAS this week: genome sequencing of weevil symbionts, retinoid X receptor deletion in lung cancer metastasis, and more.

Sequencing could help combat foodborne illnesses, according to a blog post by Food and Drug Administration officials.